Author: healthylife7

Dimerix, a clinical-stage biopharmaceutical company developing kidney disease treatments, recently announced that it had acquired DMX-652 from Mission Therapeutics. The acquisition adds a Phase II-ready acute kidney injury (AKI) programme with a differentiated mechanism, expanding Dimerix beyond its late-stage focal segmental glomerulosclerosis (FSGS) asset

Read More

Anatara Lifesciences Ltd (ASX:ANR) reported cash of $0.471 million at the end of the June 2026 quarter, down from $0.707 million at 31 March, alongside pre-clinical results showing its anti-obesity candidate compound “AOC” produced two independent measures of statistically significant activity in managing weight regain. The company is now reviewing designs for a possible open…

Read More